Piper Jaffray Expands Biotechnology Investment Banking Team With Addition of Chris Collins
June 18 2014 - 12:58PM
Business Wire
Piper Jaffray (NYSE:PJC), a leading investment bank and asset
management firm, today announced that Chris Collins has joined the
firm as a principal in its biotechnology investment banking group.
His experience includes more than 14 years in financial services
including 12 years focused on the biotechnology industry. He will
be based in the firm’s San Francisco office.
“Our market-leading healthcare platform provides strategic
advice and capital raising capabilities in one of the most
transformative and important industries in the global economy,”
commented Chad Abraham, global co-head of investment banking and
capital markets. “We see a tremendous opportunity in the
biotechnology sector and Chris is an instrumental addition to our
growing coverage team.”
Collins joins the firm from Citigroup, where he was a director
in the healthcare investment banking group focused on biotechnology
companies. He previously worked at Credit Suisse, CPC Capital
Management, Frazier Healthcare Ventures and Morgan Stanley.
Collins has represented biotechnology clients in transactions
with an aggregate transaction value exceeding $24 billion,
including over $13 billion of mergers and acquisitions and over $11
billion of capital markets transactions. He holds a bachelor’s
degree in economics from Stanford University and a master’s degree
in biotechnology from Johns Hopkins University. He is also a CFA®
charterholder.
“We’ve focused on strategically growing our biotech investment
banking franchise for several years and have made significant
headway in market share gains and revenue growth. We are very
pleased to add Chris to our team. His unique background and
industry relationships make him a highly valuable advisor to our
clients and our platform,” said Bob DeSutter, head of Piper Jaffray
healthcare investment banking.
Collins added, “Piper Jaffray has a longstanding reputation as
the investment bank of choice for healthcare companies. I look
forward to being part of one of the most respected and established
teams in the business.”
Piper Jaffray has a global healthcare investment banking and
capital markets team of more than 50 professionals. Since 2007, the
team has represented clients in 318 transactions with an aggregate
value of $54 billion. In addition, the firm’s 10 healthcare senior
research analysts cover a broad spectrum of sectors, including
biotechnology, medical technology, specialty pharmaceuticals, drug
discovery, medical diagnostics, life science tools and healthcare
services, including information technology and alternate site
providers.
About Piper Jaffray
Piper Jaffray Companies (NYSE: PJC) is an investment bank and
asset management firm headquartered in Minneapolis with offices
across the U.S. and in London, Hong Kong* and Zurich. Securities
brokerage and investment banking services are offered in the United
States through Piper Jaffray & Co., member NYSE and SIPC, and
in Europe through Piper Jaffray Ltd., authorized and regulated by
the Financial Conduct Authority. Asset management products and
services are offered through three separate investment advisory
affiliates registered with the U.S. Securities and Exchange
Commission: Advisory Research Inc., Piper Jaffray Investment
Management LLC and PJC Capital Partners LLC.
The CFA® is a registered trademark owned by CFA Institute.
Follow Piper Jaffray: LinkedIn | Facebook
© 2014 Piper Jaffray Companies, 800 Nicollet Mall, Suite 1000,
Minneapolis, Minnesota 55402-7020
Piper Jaffray CompaniesPamela Steensland,
612-303-8185pamela.k.steensland@pjc.com
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Sep 2023 to Sep 2024